度洛西汀联合舒血宁对老年抑郁轻度认知功能障碍的疗效研究

Study of Duloxetine combined with ginkgo biloba in treatment of mild cognition impairment in senile depression

目的探讨度洛西汀联合舒血宁对老年抑郁轻度认知功能障碍的疗效。方法将70例老年抑郁患者,用随机数字表法随机分为研究组(度洛西汀联合舒血宁)和对照组(度洛西汀)各35例,疗程7周。在治疗前及治疗7周后采用汉密尔顿抑郁量表(HAMD)评定疗效,蒙特利尔认知评估量表(MoCA)评估认知功能。结果研究组HAMD总分低于治疗前(P<0.01),MoCA总分均高于治疗前(P<0.05);对照组HAMD总分低于治疗前(P<0.01),MoCA总分均高于治疗前(P<0.05)。两组间比较,研究组HAMD总分与对照组比较无统计学差异(P>0.05),研究组MoCA总分高于对照组(P<0.05),且研究组治疗期间不良反应少。结论度洛西汀联合舒血宁对老年抑郁轻度认知功能障碍有明显改善,安全性好。

Objective To discuss the treatment effects of Duloxetine combined with ginkgo biloba on mild cognition impairment （MCl） in senile depression. Methods Seventy senile patients with depression were divided into trial group （ n = 35） and control group （ n = 35 ） at random. The trial group was treated with Duloxetine combined with gingko biloba and the control group only with Duloxetine. Hamihon＇ s depression （HAMD） and montreal cognitive assessment （MoCA） scales were used to evaluate the cogni- tive function betbre and after seven weeks＇ treatment, respectively. Results In the trial group, H AMD score was lower and MoCA score was higher after seven weeks＇ therapy than before （ P 〈 0.01 ; P 〈 0.05 ） , and so was in the control group （ P 〈 0.01 ; P 〈 0.05）. There was no difference in HAMD score between the two groups （P 〉 0.05）. MoCA score of the trial group was higher than that of the control group （ P 〈 0.05 ）. Moreover, the side effects of the trial group were fewer. Conclusion The treatment of Duloxetine combined with ginkgo biloba can greatly improve MCI in senile depression patients with fewer side effects.